Data on AstraZeneca vaccine insufficient for Swiss approval
Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing.
Copyright 2021 The Associated Press. All Rights Reserved
This content was published on
2 minutes
Keystone-SDA/gw
Español
es
Los datos de AstraZeneca son insuficientes para aprobación en Suiza
The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
But this did not mean that he believes the vaccine is a poor one.
“We are only saying that the company has not yet been able to prove to us that it is a good vaccine,” said Bruhin.
The approvals process, he added, was about hard data and facts. Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing, and remains in regular contact with the makers of the vaccine.
Other countries, such as the United Kingdom, have been administering the AstraZeneca vaccine for over three months – although several nations have halted vaccinations in recent days over isolated cases of blood-clotting. The European Medicines Agency has said the benefits of the Oxford-AstraZeneca jab greatly outweigh the risks and on Thursday will issue a report on its investigation into cases of blood clots.
Switzerland has ordered more than 35 million doses of Covid-19 vaccines from five manufacturers. To date Swissmedic has approved shots developed by Pfizer/BioNTech and Moderna. Roughly 4% of the population has been vaccinated so far, but delays in approval and delivery have slowed the roll-out process.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Switzerland faces fresh AT1 bond case after Credit Suisse collapse
This content was published on
A British law firm has filed a case against Switzerland in connection with the write-down of AT1 bonds during UBS's 2023 takeover of Credit Suisse.
Switzerland is Europe’s most innovative country, EU study finds
This content was published on
In the European Commission's annual ranking, the Swiss score dropped slightly in 2025, but not enough to cost it top spot.
This content was published on
The harvest volume from Swiss forests again declined last year as the importance of wood chips for energy production has increased.
Women’s Euro 2025 has been largely peaceful so far
This content was published on
After two weeks of football fever in various Swiss host cities, no major incidents have been reported so far, police say.
Planned solar park at Bern airport scaled back after talks
This content was published on
The ground-mounted plant at Belpmoos Airport will be smaller than originally planned, the parties involved said on Tuesday.
Legal action filed against Swiss purchase of Israeli drones
This content was published on
Legal action aims to put an end to the delivery of the six Elbit reconnaissance drones already plagued by delays and setbacks.
Higher direct payments fail to curb scrub encroachment on alpine pastures
This content was published on
The scrub encroachment on Swiss alpine pastures leads to the loss of grassland and damages the typical landscape. It is also responsible for the decline in biodiversity. Despite higher direct payments, the bushes continue to spread.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland could sell or give away AstraZeneca doses if regulator dithers
This content was published on
A lack of green light from medicines regulator Swissmedic could see 5.3 million doses ordered by Switzerland sent elsewhere.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.